Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers

Fig. 1

Best response by Response Evaluation Criteria in Solid Tumor (RECIST), measured as maximum percent change of tumor RECIST measurements from baseline. Tumor type (and cohort) are denoted below each bar. Green denotes partial response, yellow denotes stable disease, and red denotes progressive disease. A, alternate dose schedule; CER, cervical; EM, endometrial; ESO, esophageal; MESO, mesothelial; OV, ovarian/fallopian/peritoneal; URE, urethral; VA, vaginal

Back to article page